Vedanta Biosciences raises $27M in Series C round
The company plans to use the funding to support its various microbiome-based drug development programs in oncology, food allergy and bacterial infection.
Invesco Asset Management
The company plans to use the funding to support its various microbiome-based drug development programs in oncology, food allergy and bacterial infection.